We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Renalytix Plc | LSE:RENX | London | Ordinary Share | GB00BYWL4Y04 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.00 | -3.77% | 25.50 | 25.00 | 26.00 | 26.50 | 25.50 | 26.50 | 43,867 | 14:00:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Services, Nec | 3.4M | -46.22M | -0.4626 | -0.55 | 25.48M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/4/2024 17:30 | The company has not given any thoughts on margins, but I would compare it with Pharma where product cost is typically 20% and sales/general costs another 30% for an established product…. There would be costs anyway in operating the test, so the incremental costs of outsourcing might push the lab cost up by a further 10-20%….should still be profitable…but it does allow scalability which is key to RENX being able to penetrate the addressable market. | 1jat | |
09/4/2024 20:24 | OK.I hear what you are saying. How do you think that would translate into profit for RENX if they have to follow that kind of model? | f56 | |
09/4/2024 17:26 | F56 - how relevant is the invitae case to RENX? I expect RENX has the IP/technology and will licence testing to labs….they certainly dont have the infrastructure to set up labs, lab cost will take a chunk of the $950 tariff for the test. | 1jat | |
08/4/2024 19:27 | Invitae, the testing company, have just gone bankrupt in the US. They managed a significant turnover before running out of cash. | f56 | |
13/3/2024 16:46 | If they cant raise the run rate at Mt sinai...and Mt Sinai increases its holding in the company you wonder whats going on. Maybe both are run by idiots. My guess is it goes private in the next year. Delist and carve up between Mills, the bod and Sinai. | mr roper | |
13/3/2024 14:28 | I am encouraged the founders/champions of RENX have bought into the fund raise…..but they are the funder of last resort at the moment. The fund raise provides an immediate stay of execution for the company and will allow the sale of business process to proceed without a gun to the directors heads….however they need to recognise that either they will need to sell the business or be prepared to fund the company until it can make itself cash generative. They must hope the continued adoption in clinical standards will result in substantial demand for tests. That is what gives me hope that they can land a decent offer and sell the company. | 1jat | |
12/3/2024 09:53 | Good to see Howard Doran appointed as Business Manager to drive sales all of six months ago doesnt even list RENX as his employer. Fact he's yet another one in his mid 60s picking up a pension salary here probably means he's forgotten where he works. They know how to pick them | faz | |
12/3/2024 09:38 | this company could do a GWP...following same scenario..multi billion takeover soon | iceagefarmer | |
12/3/2024 08:36 | Numpties still buying | beatme1 | |
12/3/2024 07:42 | Told you: mortal1ty: Seen this so many times before. Compnay on its last legs, and needing capital. Vague bid spec, followed by formal sales process. Bid rarely comes. Sometimes if it does come it is at a price well below the current price. If it doesn't come emergency funding needed and business collapses. | mortal1ty | |
12/3/2024 07:41 | Will it be worth buying at 20p though | markth126 | |
12/3/2024 07:40 | I did tell people here when the bid first came out. Someone replied "someone wants to buy in early this morning". Should have listened. | mortal1ty | |
12/3/2024 07:19 | Utter disgrace | toffeeman | |
12/3/2024 07:15 | Straight from the shafting of PIs 101 guide.Condolences holders | scepticalinvestor | |
06/3/2024 11:37 | Rat has jumped shi | beatme1 | |
05/3/2024 10:49 | The $64m question (gosh that used to be an awful lot of money)….is the price at which a deal can be struck. With 100m shares in issue each £1m is roughly 1p to shareholders. You would think a large diagnostic company would know how to exploit the product and evaluate its prospects….the The Directors can really only resist if they have a viable plan B (until recently plan A that they have not been able/willing to execute). I need 125p to break even in my small speculative investment here…..I expect a significant loss, anything less than 50% is looking good now as it was down to a 95% loss at one point. | 1jat | |
05/3/2024 08:03 | Looks like another big blue day | genierub | |
04/3/2024 18:16 | sale being instigated by Harwood? | 1c3479z | |
04/3/2024 15:58 | There will be no gap up tomorrow | beatme1 | |
04/3/2024 15:58 | You want to be out now | beatme1 | |
04/3/2024 15:58 | USA will crash after hours | beatme1 | |
04/3/2024 15:58 | A few pumpers left on lse watch them run and sell before cloaeb | beatme1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions